Степень тяжести и терапия когнитивных нарушений

С увеличением продолжительности жизни в популяции увеличивается доля людей с когнитивными нарушениями (КН). В фокусе внимания современной неврологии находятся более легкие формы КН: умеренные, легкие и субъективные КН, более перспективные в отношении успешности терапии и замедления их прогрессирования. Возраст является основным фактором риска развития КН, распространенность которых в общей популяции лиц старше 65 лет достигает 10–15%. Основную роль в развитии КН играют болезнь Альцгеймера, цереброваскулярные заболевания, смешанный сосудисто-нейродегенеративный процесс и другие виды нейродегенеративных заболеваний, причем некоторые патофизиологические процессы являются для них общими. Ведущую роль в лечении додементных стадий КН играет коррекция сосудистых факторов риска. Анализируются возможности применения нимодипина в терапии КН.

1. Arvanitakis Z, Shah RC, Bennett DA. Diagnosis and management of dementia: review. JAMA. 2019 Oct 22;322(16):1589-99. doi: 10.1001/jama.2019.4782

2. Di Carlo A, Lamassa M, Baldereschi M, et al. CIND and MCI in the Italian elderly: frequency, vascular risk factors, progression to dementia. Neurology. 2007 May 29;68(22):1909- 16. doi: 10.1212/01.wnl.0000263132.99055.0d

3. Ganguli M, Chang CC, Snitz BE, et al. Prevalence of mild cognitive impairment by multiple classifications: The Monongahela-Youghiogheny Healthy Aging Team (MYHAT) project. Am J Geriatr Psychiatry. 2010 Aug;18(8):674-83. doi: 10.1097/JGP.0b013e3181cdee4f

4. Larrieu S, Letenneur L, Orgogozo JM, et al. Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology. 2002 Nov 26;59(10):1594-9. doi: 10.1212/01.wnl.0000034176.07159.f8

5. Roberts RO, Geda YE, Knopman DS, et al. The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology. 2008;30(1):58- 69. doi: 10.1159/000115751. Epub 2008 Feb 7.

6. Sonnen JA, Larson EB, Crane PK, et al. Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol. 2007 Oct;62(4):406-13. doi: 10.1002/ana.21208

7. White L, Petrovitch H, Hardman J, et al. Cerebrovascular pathology and dementia in autopsied Honolulu-Asia Aging Study participants. Ann N Y Acad Sci. 2002 Nov;977:9-23. doi: 10.1111/j.1749-6632.2002.tb04794.x

8. Захаров ВВ. Всероссийская программа исследований эпидемиологии и терапии когнитивных расстройств в пожилом возрасте («Прометей»). Неврологический журнал. 2006;(11):27-32.

9. American Psychiatric Association. Neurocognitive disorders. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). 5th ed. Washington, DC: American Psychiatric Association; 2013. Ch. 20.

10. World Health Organization: Dementia: A Public Health Priority; 2012.

11. Raz L, Knoefel J, Bhaskar K. The neuropathology and cerebrovascular mechanisms of dementia. J Cereb Blood Flow Metab. 2016 Jan;36(1):172-86. doi: 10.1038/jcbfm.2015.164

12. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004 Sep;256(3):183-94. doi: 10.1111/j.1365-2796.2004.01388.x

13. Petersen RC, Knopman DS, Boeve BF, et al. Mild cognitive impairment: 10 years later. Arch Neurol. 2009 Dec;66(12):1447-55. doi: 10.1001/archneurol.2009.266

14. Парфенов ВА, Захаров ВВ, Преображенская ИС. Когнитивные расстройства. Москва; 2014. 192 с.

15. Захаров ВВ. Эволюция когнитивного дефицита: легкие и умеренные когнитивные нарушения. Неврология, нейропсихиатрия и психосоматика. 2012;(2):16-21. doi: 10.14412/2074-2711-2012-376 (In Russ.)].

16. Petersen RC. Mild Cognitive Impairment. Continuum (Minneap Minn). 2016 Apr;22(2 Dementia):404-18. doi: 10.1212/CON.0000000000000313

17. Яхно НН. Когнитивные расстройства в неврологической клинике. Неврологический журнал. 2006;11(Прил. 1):4-12.

18. Bassett SS, Folstein MF. Memory complaint, memory performance, and psychiatric diagnosis: a community study. J Geriatr Psychiatry Neurol. Apr-Jun 1993;6(2):105-11. doi: 10.1177/089198879300600207

19. Matthews FE, Arthur A, Barnes LE, et al. A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the Cognitive Function and Ageing Study I and II. Lancet. 2013 Oct 26;382(9902):1405-12. doi: 10.1016/S0140-6736(13)61570-6. Epub 2013 Jul 17.

20. Jessen F, Amariglio RE, van Boxtel M, et al. Subjective Cognitive Decline Initiative (SCD-I) Working Group. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement. 2014 Nov;10(6):844-52. doi: 10.1016/j.jalz.2014.01.001. Epub 2014 May 3.

21. Striepens N, Scheef L, Wind A, et al. Volume loss of the medial temporal lobe structures in subjective memory impairment. Dement Geriatr Cogn Disord. 2010;29(1):75-81. doi: 10.1159/000264630. Epub 2010 Jan 28.

22. Mosconi L, De Santi S, Brys M, et al. Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints. Biol Psychiatry. 2008 Mar 15;63(6):609-18. doi: 10.1016/j.biopsych.2007.05.030. Epub 2007 Aug 27.

23. Perrotin A, Mormino EC, Madison CM, et al. Subjective cognition and amyloid deposition imaging: A Pittsburgh Compound B positron emission tomography study in normal elderly individuals. Arch Neurol. 2012 Feb;69(2):223-9. doi: 10.1001/archneurol.2011.666

24. Amariglio RE, Becker JA, Carmasin J, et al. Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. Neuropsychologia. 2012 Oct;50(12):2880-6. doi: 10.1016/j.neuropsychologia.2012.08.011. Epub 2012 Aug 23.

25. Hessen E, Eckerström M, Nordlund A, et al. Subjective Cognitive Impairment Is a Predominantly Benign Condition in Memory Clinic Patients Followed for 6 Years: The Gothenburg-Oslo MCI Study. Dement Geriatr Cogn Dis Extra. 2017 Feb 2;7(1):1-14. doi: 10.1159/000454676. eCollection Jan-Apr 2017.

26. Eckerström M, Berg AI, Nordlund A, et al. High Prevalence of Stress and Low Prevalence of Alzheimer Disease CSF Biomarkers in a Clinical Sample with Subjective Cognitive Impairment. Dement Geriatr Cogn Disord. 2016;42(1-2):93- 105. doi: 10.1159/000448326. Epub 2016 Sep 9.

27. Парфенов ВА, Старчина ЮА, Яхно НН. Эпросартан (теветен) в профилактике повторного инсульта и когнитивных нарушений. Неврологический журнал. 2007;(1):46-51.

28. Парфенов ВА, Хасанова ДР. Ишемический инсульт. Москва: МИА; 2012. 288 с.

29. Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care. Lancet. 2017 Dec 16;390(10113):2673-734. doi: 10.1016/S0140-6736(17)31363-6. Epub 2017 Jul 20.

30. Van de Glind EMM, van Enst WA, van Munster BC, et al. Pharmacological Treatment of Dementia: A Scoping Review of Systematic Reviews. Dement Geriatr Cogn Disord. 2013;36(3-4):211-28. doi: 10.1159/000353892. Epub 2013 Aug 12.

31. Tisher A, Salardini A. A Comprehensive Update on Treatment of Dementia. Semin Neurol. 2019 Apr;39(2):167-78. doi: 10.1055/s0039-1683408. Epub 2019 Mar 29.

32. Amieva H, Ouvrard C, Giulioli C, et al. Self-Reported Hearing Loss, Hearing Aids, and Cognitive Decline in Elderly Adults: A 25-Year Study. J Am Geriatr Soc. 2015 Oct;63(10):2099-104. doi: 10.1111/jgs.13649

33. Uchida Y, Nishita Y, Tange C, Sugiura S. The Longitudinal Impact of Hearing Impairment on Cognition Differs According to Cognitive Domain. Front Aging Neurosci. 2016 Aug 22;8:201. doi: 10.3389/fnagi.2016.00201. eCollection 2016.

34. Fritze T, Teipel S, Ovari A, et al. Hearing Impairment Affects Dementia Incidence. An Analysis Based on Longitudinal Health Claims Data in Germany. PLoS One. 2016 Jul 8;11(7):e0156876. doi: 10.1371/journal.pone.0156876. eCollection 2016.

35. Jefferis JM, Mosimann UP, Clarke MP. Cataract and Cognitive Impairment: A Review of the Literature. Br J Ophthalmol. 2011 Jan;95(1):17-23. doi: 10.1136/bjo.2009.165902. Epub 2010 Aug 31.

36. Roberts RO, Cha RH, Mielke MM, et al. Risk and protective factors for cognitive impairment in persons aged 85 years and older. Neurology. 2015 May 5;84(18):1854-61. doi: 10.1212/WNL.0000000000001537. Epub 2015 Apr 8.

37. Andel R, Crowe M, Pedersen NL, et al. Physical exercise at midlife and risk of dementia three decades later: a population-based study of Swedish twins. J Gerontol A Biol Sci Med Sci. 2008 Jan;63(1):62-6. doi: 10.1093/gerona/63.1.62

38. Ahlskog JE, Geda YE, Graff-Radford NR, et al. Physical Exercise as a Preventive or Disease-Modifying Treatment of Dementia and Brain Aging. Mayo Clin Proc. 2011 Sep;86(9):876-84. doi: 10.4065/mcp.2011.0252

39. Morris MC, Tangney CC, Wang Y, et al. MIND diet associated with reduced incidence of Alzheimer's disease. Alzheimers Dement. 2015 Sep;11(9):1007-14. doi: 10.1016/j.jalz.2014.11.009. Epub 2015 Feb 11.

40. Yaffe K, Laffan AM, Harrison SL, et al. Sleep-Disordered Breathing, Hypoxia, and Risk of Mild Cognitive Impairment and Dementia in Older Women. JAMA. 2011 Aug 10;306(6):613- 9. doi: 10.1001/jama.2011.1115

41. Chang WP, Liu ME, Chang WC. Sleep apnea and the risk of dementia: a population-based 5-year follow-up study in Taiwan. PLoS One. 2013 Oct 24;8(10):e78655. doi: 10.1371/journal.pone.0078655. eCollection 2013.

42. Cooper C, Sommerlad A, Lyketsos CG, Livingston G. Modiёable predictors of dementia in mild cognitive impairment: a systematic review and meta-analysis. Am J Psychiatry. 2015 Apr;172(4):323-34. doi: 10.1176/appi.ajp.2014.14070878. Epub 2015 Feb 20.

43. Saczynski JS, Beiser A, Seshadri S, et al. Depressive symptoms and risk of dementia: the Framingham Heart Study. Neurology. 2010 Jul 6;75(1):35-41. doi: 10.1212/WNL.0b013e3181e62138

44. Dotson VM, Beydoun MA, Zonderman AB. Recurrent depressive symptoms and the incidence of dementia and mild cognitive impairment. Neurology. 2010 Jul 6;75(1):27-34. doi: 10.1212/WNL.0b013e3181e62124

45. Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015 Jun 6;385(9984):2255-63. doi: 10.1016/S0140-6736(15)60461-5. Epub 2015 Mar 12.

46. McShane R, Areosa Sastre A, Minakaran N. Memantine fordementia. Cochrane Database Syst Rev. 2006 Apr 19;(2):CD003154. doi: 10.1002/14651858.CD003154.pub5

47. Emre M, Tsolaki M, Bonuccelli U, et al; 11018 Study Investigators. Memantine for patients with Parkinson's disease dementia ordementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010 Oct;9(10):969-77. doi: 10.1016/S1474-4422(10)70194-0. Epub 2010 Aug 20.

48. Howard R, McShane R, Lindesay J, et al. Nursing home placementin the donepezil and memantine in moderate to severe Alzheimer's disease (DOMINO-AD) trial: secondary and post-hoc analyses. Lancet Neurol. 2010 Oct;9(10):969-77. doi: 10.1016/S1474-4422(10)70194-0. Epub 2010 Aug 20.

49. Diniz BS, Pinto JA, Gonzaga MCG. To treat or not to treat? A meta-analysis of the use of cholinesterase inhibitors in mild cognitive impairment for delaying progression to Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci. 2009 Jun;259(4):248-56. doi: 10.1007/s00406-008-0864-1. Epub 2009 Feb 17.

50. Russ TC. Cholinesterase Inhibitors Should Not Be Prescribed for Mild Cognitive Impairment. Evid Based Med. 2014 Jun;19(3):101. doi: 10.1136/eb-2013-101687. Epub 2014 Jan 30.

51. Winblad B, Gauthier S, Scinto L, et al. Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology. 2008 May 27;70(22):2024-35. doi: 10.1212/01.wnl.0000303815.69777.26. Epub 2008 Mar 5.

52. Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005 Jun 9;352(23):2379-88. doi: 10.1056/NEJMoa050151. Epub 2005 Apr 13.

53. Tomassoni D, Lanari A, Silvestrelli G, et al. Nimodipine and Its Use in Cerebrovascular Disease: Evidence from Recent Preclinical and Controlled Clinical Studies. Clin Exper Hypertens. 2008 Nov;30(8):744-66. doi: 10.1080/10641960802580232

54. Lopez-Arrieta J, Birks J. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev. 2002;(3):CD000147. doi: 10.1002/14651858.CD000147

55. Knopman DS. Treatment of mild cognitive impairment and prospects for prevention of Alzheimer's disease. In: Petersen RC, ed. Mild Cognitive Impairment: Aging to Alzheimer's Disease. Oxford: Oxford University Press; 2003. P. 243-58.

56. Lopez-Arrieta J. Nimodipine. In: Qizilbash N et al, eds. Evidence-Based Dementia Practice. Oxford: Blackwell Science; 2002. P. 537-40.

57. Ghanbari-Maman A, Ghasemian-Roudsari F, Aliakbari S, et al. Calcium Channel Blockade Ameliorates Endoplasmic Reticulum Stress in the Hippocampus Induced by Amyloidopathy in the Entorhinal Cortex. Iran J Pharm Res. Summer 2019;18(3):1466-76. doi: 10.22037/ijpr.2019.111532.13216

58. Wang P, Wang Y, Feng T, et al. Rationale and design of a double-blind,placebo-controlled, randomized trial to evaluate the safety and efficacy of nimodipine in preventing cognitive impairment in ischemic cerebrovascular events (NICE). BMC Neurol. 2012 Sep 5;12:88. doi: 10.1186/1471-2377-12-88

59. Ferszt R, Kanowski S. Nimodipine in the treatment of dementia. Drugs Today. 1998 Sep;34(9):767-76. doi: 10.1358/dot.1998.34.9.485275

60. Avery RB, Johnson D. Multiple channel types contribute to the low-voltage-activated calcium current in hippocampal CA3 pyramidal neurons. J Neurosci. 1996 Sep 15;16(18):5567-82. doi: 10.1523/JNEUROSCI.16-18-05567.1996

61. Campbell LW, Hao SY, Thibault O, et al. Aging changes in voltage-gated calcium currents in hippocampal CA1 neurons. J Neurosci. 1996 Oct 1;16(19):6286-95. doi: 10.1523/JNEUROSCI.16-19-06286.1996